Considerations for Improving Equity and Access to CAR-T Therapies.
New manufacturing and international cooperation approaches could make expensive cell therapies more accessible to patients.
This PubMed-indexed study examined there are significant barriers to equitable access to cell therapies among which include the high costs of treatment, complex logistics from manufacture to bedside and the substantial economic gradients that exist between health. The abstract reports four Key Drivers of the Paradigm shift: (1) New Manufacturing Models, (2) Technological Advancements, (3) Innovative Regulatory Approaches and (4) International Cooperation.
What the study was
- Study design
- Narrative Review
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Transplantation and cellular therapy
Why it surfaced
Conservative triage based on the PubMed abstract: narrative review with direct watchlist relevance; score reflects metadata and abstract-level evidence only.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.